About Canopy Growth Corporation - Common Shares (CGC)
Canopy Growth Corp is a leading player in the cannabis industry, focusing on the production and distribution of a wide range of cannabis products. The company is engaged in cultivating and processing cannabis for both medical and recreational purposes, offering various forms such as dried flower, oils, edibles, and beverages. With a commitment to innovation, Canopy Growth invests in research and development to create high-quality products that meet consumer demands and adhere to evolving regulations. The company also emphasizes sustainability and responsible business practices, aiming to shape the future of cannabis consumption and enhance the overall experience for consumers. Read More
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (Nasdaq: CGC) today announced its financial results for the fourth quarter ended March 31, 2025 ("Q4 FY2025") and the fiscal year ended March 31, 2025 ("FY2025") and the filing of the Company’s Annual Report on Form 10-K for FY2025 (the "Form 10-K"), including the audited consolidated financial statements for FY2025 and the unqualified report thereon of the Company’s independent registered public accounting firm. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Canopy Growth Corporation (“Canopy” or the “Company”) (NASDAQ: CGC) and certain officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-01877, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Canopy securities between May 30, 2024 and February 6, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Canopy Growth Corporation (“Canopy” or the “Company”) (NASDAQ: CGC) and certain officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-01877, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Canopy securities between May 30, 2024 and February 6, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Canopy Growth Corporation (NASDAQ:CGC), Viatris Inc. (NASDAQ: VTRS), Bakkt Holdings, Inc. (NYSE:BKKT), and Cerevel Therapeutics Holdings, Inc. (CERE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
In a closely split 5-4 ruling, the U.S. Supreme Court recently sided with a commercial truck driver who sued three CBD firms under the federal RICO statute. The driver, Douglas Horn, claimed he was fired after a drug test came back positive for THC, despite using a CBD product that was labeled as THC-free.
